Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01279187 · ClinicalTrials.gov registry record · Phase 2
The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone
A Phase 2 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01279187 is a Phase 2 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 27 participants.
The verdict
NCT01279187, a Phase 2 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
Good bone healing and bone build-up are necessary for the success of dental implants. Research in animals and humans has shown that a drug, called Forteo, can increase bone build-up and bone strength over time. Forteo has been approved by the Food and Drug Administration (FDA) for use in patients with a condition where bone is broken down and weakened, called osteoporosis. The investigators do not know, however, whether Forteo is effective for use in humans for improving bone healing after implant placement, and whether it will have the same bone-building and bone-strengthening effects as for patients with osteoporosis. This research study is being done to learn what effect 7 weeks of treatment with Forteo will have on bone build-up and strengthening of bone for patients receiving implants.
Interventions
- DRUG Placebo
- DRUG Teriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01279187
The ClinicalTrials.gov registry entry for NCT01279187 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01279187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01279187 about?
NCT01279187 is a clinical study titled "The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone". Good bone healing and bone build-up are necessary for the success of dental implants. Research in animals and humans has shown that a drug, called Forteo, can increase bone build-up and bone strength over time. Forteo has been approved by the Food and Drug Administration (FDA) for use in patients wi...
What is the current status of trial NCT01279187?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2011-02. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01279187?
The interventions under investigation include: Placebo (DRUG), Teriparatide (DRUG).
Who is sponsoring clinical trial NCT01279187?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.